Generic Firms Object To Policy Behind Residual Solvents Deficiency Letters
Executive Summary
FDA's Office of Generic Drugs has interpreted a new pharmacopoeial standard for residual solvents in an unexpectedly rigorous manner, rejecting dozens of applications and raising the ire of generic drug manufacturers
You may also be interested in...
In Final Guidance On Residual Solvents, FDA Allows Control, Not Just Testing, Verification
Agency accepts industry comments on testing issue, but document may still contain hurdles for approval of some generic drugs.
FDA Offers More Flexibility on Residual Solvents in Generic Drug Applications
FDA's Office of Generic Drugs has taken a more flexible approach in implementing the U.S. Pharmacopeia's General Chapter <467> on residual solvents
FDA Offers More Flexibility on Residual Solvents in Generic Drug Applications
FDA's Office of Generic Drugs has taken a more flexible approach in implementing the U.S. Pharmacopeia's General Chapter <467> on residual solvents